Yanling Qu
Yuncheng, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial.
Journal: Drugs
Published: December 24, 2025
Efficacy and safety of Shuxuening injection in patients with unstable angina: a multicenter, randomized, placebo-controlled trial.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: March 09, 2025
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.
Journal: Cardiovascular diabetology
Published: January 21, 2025
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab.
Journal: Pharmacological research
Published: March 26, 2024
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.
Journal: The Lancet regional health. Western Pacific
Published: May 31, 2023
Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.
Journal: Lipids in health and disease
Published: January 06, 2023
Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.
Journal: JACC. Asia
Published: November 16, 2022
A Nomogram for Predicting Survival in Patients With Colorectal Cancer Incorporating Cardiovascular Comorbidities.
Journal: Frontiers in cardiovascular medicine
Published: February 14, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026